Globally, three GnRH antagonists have been approved – though not all are available in all countries. These are elagolix (not available outside of the USA), relugolix and linzagolix. As elagolix is not approved outside of the USA it will not be included in this survey. While they are all part of the same class of treatment, there are important differences between them – which include how they must be taken, their potential to cause hypoestrogenic issues, their tolerability profile and if and how they can be used in special populations1-3